Quinn Emma, Jit Mark, Newall Anthony T
NSW Ministry of Health , Sydney , Australia.
Expert Rev Pharmacoecon Outcomes Res. 2014 Jun;14(3):425-35. doi: 10.1586/14737167.2014.908713. Epub 2014 Apr 16.
Evidence has shown that quadrivalent influenza vaccines containing all four subtypes are safe and immunogenic. However, to date there have been few published studies exploring the population-level clinical and economic impact of quadrivalent compared to trivalent influenza vaccines. Economic evaluation studies need to be conducted in order to inform country-level decision making about whether (and how to) introduce and replace the current trivalent influenza vaccines with quadrivalent influenza vaccination programs. Several key issues associated with estimating the clinical and economic impact of the trivalent versus quadrivalent vaccines are discussed in this article, particularly the complexities involved in estimating the incremental preventable disease and economic burden. Other factors, such as the indirect (herd) protection from quadrivalent influenza vaccination and the timing of the replacement of trivalent influenza vaccination programs are also discussed.
有证据表明，包含全部四种亚型的四价流感疫苗是安全且具有免疫原性的。然而，迄今为止，很少有已发表的研究探讨与三价流感疫苗相比，四价流感疫苗在人群层面的临床和经济影响。需要开展经济评估研究，以便为国家层面关于是否（以及如何）引入四价流感疫苗接种计划并取代当前三价流感疫苗的决策提供依据。本文讨论了与评估三价和四价疫苗的临床和经济影响相关的几个关键问题，特别是在估计增量可预防疾病和经济负担方面所涉及的复杂性。还讨论了其他因素，如四价流感疫苗接种的间接（群体）保护作用以及三价流感疫苗接种计划的替换时机。
